{"meshTagsMajor":["MAP Kinase Signaling System"],"meshTags":["Animals","Carcinoma, Pancreatic Ductal","Cell Transformation, Neoplastic","Extracellular Signal-Regulated MAP Kinases","Humans","MAP Kinase Signaling System","Mitogen-Activated Protein Kinase Kinases","Pancreatic Neoplasms","Proto-Oncogene Proteins B-raf"],"meshMinor":["Animals","Carcinoma, Pancreatic Ductal","Cell Transformation, Neoplastic","Extracellular Signal-Regulated MAP Kinases","Humans","Mitogen-Activated Protein Kinase Kinases","Pancreatic Neoplasms","Proto-Oncogene Proteins B-raf"],"genes":["RAF","MEK","KRAS","RAF","mitogen-activated protein kinase","MAPK","extracellular signal-regulated kinase","ERK","MEK"],"organisms":["10090"],"publicationTypes":["Comment","Journal Article"],"abstract":"Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas.","title":"RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.","pubmedId":"22886659"}